Armata Pharmaceuticals
ARMP
14 hedge funds and large institutions have $750K invested in Armata Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
7% less funds holding
Funds holding: 15 → 14 (-1)
26% less capital invested
Capital invested by funds: $1.02M → $750K (-$266K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.4K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$10.5K |
| 4 |
SF
Synovus Financial
Columbus,
Georgia
|
+$6.79K |
| 5 |
Bank of New York Mellon
New York
|
+$5.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$589K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$123K |
| 3 |
Renaissance Technologies
New York
|
-$31K |
| 4 |
Goldman Sachs
New York
|
-$7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $507K | -$589K | -8,671 | -80% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $88K | +$22.1K | +325 | +29% |
|
|
MP
3
MSD Partners
New York
| $65K | – | – | – |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $21K | – | – | – |
|
|
FWM
5
Frontier Wealth Management
Kansas City,
Missouri
| $17K | -$1.43K | -21 | -7% |
|
|
SF
6
Synovus Financial
Columbus,
Georgia
| $11K | +$6.79K | +100 | +127% |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $11K | +$12.4K | +183 | New |
|
|
8
Northern Trust
Chicago,
Illinois
| $9K | +$10.5K | +155 | New |
|
9
Geode Capital Management
Boston,
Massachusetts
| $7K | – | – | – |
|
|
VKH
10
Virtu KCG Holdings
New York
| $6K | -$123K | -1,803 | -95% |
|
|
11
Bank of New York Mellon
New York
| $5K | +$5.71K | +84 | New |
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
|
13
Renaissance Technologies
New York
| – | -$31K | -500 | Closed |
|
|
14
Goldman Sachs
New York
| – | -$7K | -112 | Closed |
|
|
15
UBS Group
Zurich,
Switzerland
| – | -$5K | -74 | Closed |
|
16
BlackRock
New York
| – | +$408 | +6 | New |
|
ARMP Hedge Fund Activity: Q1 2017 in Review
14 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q1 2017, worth a combined $750K — down 26% from $1.02M a quarter earlier.
Fund positioning in ARMP was balanced in Q1 2017: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $22.1K. The largest seller was Sabby Management, cutting an estimated $589K.
- 14 institutional investors held Armata Pharmaceuticals (ARMP) as of Q1 2017, down from 15 in Q4 2016.
- Funds reported $750K of Armata Pharmaceuticals stock for Q1 2017, down 26% quarter-over-quarter.
- 4 funds opened new Armata Pharmaceuticals positions in Q1 2017 and 4 closed out, a net change of 0 holders.
- The largest Armata Pharmaceuticals buyer in Q1 2017 was Vanguard Group, an estimated $22.1K added.
- The largest Armata Pharmaceuticals seller in Q1 2017 was Sabby Management, an estimated $589K sold.
Based on aggregated 13F filings for Q1 2017.